Sep. 10 at 11:16 PM
$CPIX Given management's multiple investor miscommunications, I'd say the stock is not worth 2x cash. Solid management does not fail to deliver promised data. If it does fail to deliver data, it explains why. and when it will be delivered. Solid management, which lacks drug development experience, relies on a CRO to gather data, interpret data, and engage with FDA. Responsible management tells the investor base if it employs a CRO. A responsible management employs a biotech investment bank/M and A biotech law firm, thus knowing what the various indications are worth and knows to whom the company can partner or sell the indications and at what price. A responsible management characterizes the data, if the full data set is, as yet, incomplete. Despite all this the company is worth hanging onto, if you believe, as we do that, the drug's biomechanics, safety and ease of use, should position the drug for potential approval in DMD, and further drug development in Cancer, and Scleroderma.
